Colorectal Cancer (CRC) is the third most prevalent cancer in men and women. Up to 15%
of CRCs display microsatellite instability (MSI). MSI is reflective of a deficient mismatch …

Context.—The US Food and Drug Administration (FDA) approved immune checkpoint
inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair …

It was a century ago that Warthin, a pathologist, first described the clinical condition now
known as Lynch syndrome. One hundred years later, our understanding of this syndrome …

Background Immunohistochemical staining for mismatch repair proteins is efficient and
widely used to identify mismatch repair defective tumors. The tumors typically show uniform …

Colorectal cancer (CRC) incidence and mortality are constantly decreasing, but CRC still
remains the third most prevalent cancer and the third most common cause of cancer death in …

Aim Lynch syndrome (LS) accounts for 2–4% of all colorectal cancer (CRC) cases, and is
associated with an increased risk of developing metachronous colorectal cancer (mCRC) …

Mismatch repair (MMR) testing on all new cases of colorectal cancer (CRC) has customarily
been preferably performed on surgical specimens, as more tissue is available; however …

Universal screening for mismatch repair deficiency (dMMR) in cancer is increasingly being
implemented to detect Lynch syndrome and aid in treatment decisions. The mismatch repair …

Primary vulvar cancer may be safely treated with radical/wide local resection. In case of
other suspicious lesion or multifocal disease, radical vulvectomy is performed. Patients with …

Immunohistochemistry (IHC) testing for mismatch repair proteins (MMRP) is currently being
used primarily in colorectal cancer resection specimens. We aimed to compare the results of …